the flowers in all of their glory
#utdr #deltarune #undertale #tobyfox #jnj #jacknjellify #bfdi #bfdia #idfb #bfb #tpot #bfdie #battlefordreamisland

the flowers in all of their glory
#utdr #deltarune #undertale #tobyfox #jnj #jacknjellify #bfdi #bfdia #idfb #bfb #tpot #bfdie #battlefordreamisland
StratIQ morning trading brief — Oct 14 🌅
Mixed start to the day.
Top driver: Johnson & Johnson bounce after a hard selloff: -5.7% Tue on a MedTech miss, even as it beat and….
Watching: $JNJ, $BX.
https://stratiqai.app/track-record?src=bluesky
Not financial advice.
Key Mover for Oct 13: $JNJ (▼-5.73%)
Large-cap healthcare weakness was unusually sharp, with a 5.7% one-day decline.
Anomalous Activity for Oct 13: $JNJ
$JNJ is one of the clearest divergent outliers today: Capital Flow +5.0σ, Relative Return -3.5σ, Relative Gap -2.8σ. Prior flow readings were muted, so this looks like a fresh burst of activity with weak relative price action.
#JNJ $JNJ
Anomalously high trading volume detected. False resistance breakout. False seller zone breakout. Buyer zone tested. Local minimum updated.
Johnson & Johnson Raises 2026 Sales Outlook After 5.9% Quarterly Growth Johnson & Johnson reported $25.4 billion of third-quarter sales and raised...
https://www.narrowit.com/news/johnson-johnson-q3-sales-guidance-talc-charge-2026-10-13
#JohnsonJohnson #JNJ #ThirdQuarter2026 #HealthCareEarnings
📉 $JNJ down -5.24% amid broad market rotation.
Trading at ~5.1× its typical daily move.
#JNJ #Healthcare
Full breakdown: https://premarketprice.com/analysis/JNJ?utm_source=bluesky&utm_medium=social&utm_campaign=movers
$JNJ Q3 2026
Intäkter +5.9% YoY
EPS -95.8% YoY
• Innovative Medicine-omsättning +11,1% YoY
• Nettoresultat (GAAP) föll 95,9% till 210 miljoner dollar
• Rättsliga kostnader på 5,5 miljarder dollar påverkar resultatet
#JNJ $JNJ
Resistance tested. Seller zone tested. Buyer zone formed. Local minimum confirmed.
Closing Bell: Market Wrap
- JNJ trades at 263.02, up 0.60% on the session, as Wall Street braces for Q3 results after the closing bell.
- Analysts expect earnings of $2.53 a share, down 9.6%, on revenue of $25.38B, up 5.8%.
#OnThisDay in 1993, Matthew Ashford last appeared as Jack Deveraux, ending a 6 year run. He would return in 2001 #JnJ #ClassicDays #Days #DaysofourLives
🩺 J&J Hits Record $157.44 as Traders Brace for October 13 Catalyst
Johnson & Johnson climbed 2.23% to $157.44, a 52-week high and its best level since October 2026, with the stock up 28.72% year to date.
🩺 J&J Hits Record $157.44 as Traders Brace for October 13 Catalyst
Johnson & Johnson climbed 2.23% to $157.44, a 52-week high and its best level since October 2026, with the stock up 28.72% year to date.
Scorecard updated for Johnson & Johnson Common Stock (JNJ). Score: 69/100 (Bullish Setup). Stance: Hold Existing Exposure. #JNJ
Quick fair value update for $JNJ. Current price: $261.44 vs model estimate of $246.90. Rated as FAIRLY VALUED with -5.6 implied gap. #JNJ
🩺 Icotyde Holds 72% Skin Clearance at Two Years in Psoriasis Trial
Johnson & Johnson said phase 3 ICONIC-LEAD data show at least 72% of plaque psoriasis patients on Icotyde (icotrokinra) kept high skin clearance past two years of treatment.
Rep. Lloyd Doggett (D-TX) disclosed 1 trade:
Traded: Sep 8 | Disclosed: Oct 5
Bought: $JNJ ($1K-$15K)